Prevents bronchospasm. ANDA 90297, held by Teva Pharms USA. Levalbuterol Hydrochloride.
As of Nov 16, 2026, ANDA 90297 (Levalbuterol Hydrochloride), held by Teva Pharms USA, was first approved by FDA on Apr 26, 2013, with 4 approved supplements and 0 published complete response letters.
Levalbuterol inhalation solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. Levalbuterol inhalation solution USP is a beta 2 -adrenergic agonist indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 26, 2013 | Original application | Approved | None posted |
| Levalbuterol HydrochlorideEQ 0.0103% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Levalbuterol HydrochlorideEQ 0.021% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Levalbuterol HydrochlorideEQ 0.042% BASE · solution;inhalation | Levalbuterol Hydrochloride | Rx |
| Mar 22, 2019 | Supplement 8Manufacturing · Standard review | Approved | None posted |
| Mar 24, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 24, 2016 | Supplement 4Labeling · Standard review | Approved | None posted |
| Mar 24, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 26, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters